Результаты поиска

Management of patients with an electrical storm or clustered ventricular arrhythmias: a clinical consensus statement of the European Heart Rhythm Association of the ESC-endorsed by the Asia-Pacific Heart Rhythm Society, Heart Rhythm Society, and Latin-American Heart Rhythm Society.

Electrical storm (ES) is a state of electrical instability, manifesting as recurrent ventricular arrhythmias (VAs) over a short period of time (three or more episodes of sustained VA within 24 h, separated by at least 5 min, requiring termination by an intervention). The clinical presentation can vary, but ES is usually a cardiac emergency. Electrical storm mainly affects patients with structural or primary electrical heart disease, often with an implantable cardioverter-defibrillator (ICD). Management of ES requires a multi-faceted approach and the involvement of multi-disciplinary teams, but

Совпадение в полном тексте источника
… Beta-blocker therapy can decrease the risk of sudden cardiac death. 202 Specifically, in the setting of ES, propranolol has demonstrated better efficacy compared with metoprolol. 149 Of note, the effects of sympathetic activation extend beyond those influenced by BB therapy. … monomorphic VT, occasional TdP), increase pacing threshold | Heart rate, blood pressure, ECG (QRS duration, QT interval) | Severe bradycardia and/or high-degree AV block and/or severe intraventricular conduction delay in the absence of a pacemaker, ischaemia, SHD, BrS, myasthenia gravis Class II | Metoprolol …

Совпадение с Такаясу Артеритом и множественным склерозом: обзор скрипта и доклад по делу.

ВВЕДЕНИЕ: Такайасу-артерит (ТА) и множественный склероз (МС) являются как иммунизированными заболеваниями, которые могут сосуществовать, при этом ТА вызывает сосудистое воспаление, а MS - обезвоживание, вызванное аберрантной активностью Т-клеток. Совпадение этих условий подчеркивает наличие общих иммунных механизмов, таких, как регулирование " Т-клеток " и высвобождение цитокина, что подчеркивает необходимость нюансированного понимания их взаимодействия, которое изучается в ходе описательного обзора зарегистрированных случаев. Мы рассказываем обо всех зарегистрированных случаях насил

Совпадение в полном тексте источника
… He had started with metoprolol because of continuing hypertension. Otherwise, thrombocytes had normalized, which confirmed our hypothesis of an IFN-induced thrombocytopenia “ex juvantibus.” … We changed amlodipine to lercanidipine because of ankle edema, increased metoprolol which the general practitioner had started, and discharged the patient again. The vessel wall changes on ultrasound were stable after 2 weeks and had disappeared after 3 months without treatment. …

Chronic stress in solid tumor development: from mechanisms to interventions.

Chronic stress results in disturbances of body hormones through the neuroendocrine system. Cancer patients often experience recurrent anxiety and restlessness during disease progression and treatment, which aggravates disease progression and hinders treatment effects. Recent studies have shown that chronic stress-regulated neuroendocrine systems secret hormones to activate many signaling pathways related to tumor development in tumor cells. The activated neuroendocrine system acts not only on tumor cells but also modulates the survival and metabolic changes of surrounding non-cancerous cells.

Совпадение в полном тексте источника
… , sotalol | No | No TNBC | 800 | 4 | Associate with a lower risk of BC recurrence and death [ 142 ] | Carvedilol, sotalol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol | No | No EOC | 185 | Not applicable | Perioperative BBs use is associated with longer OS among patients undergoing primary … disease-free survival (DFS), and OS [ 168 ] | Not reported | No | Radiation therapy NSCLC | 1753 | 3 | Not affect OS in stage III inoperable NSCLC [ 158 ] | Propranolol | No | No Metastatic NSCLC | 107 | Not applicable | BBs use during CT may be associated with an improved OS for patients [ 147 ] | Metoprolol …

Pharmacological interventions for hypertension in children.

BACKGROUND: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data … ut not diastolic blood pressure (-4.80, 95% CI -9.50 to 0.10) (low-quality evidence). Beta blocker (metoprolol, one trial, n = 140), when compared with placebo , significantly reduced systolic blood pressure by 4.20 mmHg (95% CI -8.12 to -0.28) but not diastolic blood pressure (-3.20 mmHg 95% CI -7.12 to 0.72) (low-quality evidence). Beta blocker/diuretic co …

Cochrane in context: pharmacological interventions for hypertension in children.

BACKGROUND: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data … ) but not diastolic blood pressure (.4.80, 95% . .9.50 to 0.10) (low-quality evidence). ..-Blocker (metoprolol, one trial, n=140), when compared with placebo, significantly reduced systolic blood pressure by 4.20 mmHg (95% confidence interval .8.12 to .0.28) but not diastolic blood pressure (.3.20 mmHg 95% confidence interval .7.12 to 0.72) (low-quality evid …

Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is the first approved histone deacetylase (HDAC) inhibitor for the treatment of cutaneous T-cell lymphoma after progressive disease following two systemic therapies. The rats were randomly divided into SAHA groups (low, medium and high dosage) and control group. The SAHA group rats were given 12.3, 24.5, and 49 mg/kg SAHA, respectively, by continuous intragastric administration for 7 days. The influence of SAHA on the activities of CYP450 isoforms CYP2B6, CYP1A2, CYP2C19, CYP2D6 and CYP2C9 were evaluated by cocktail method, they were responsed

Pharmacological interventions for hypertension in children.

BACKGROUND: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data … ut not diastolic blood pressure (-4.80, 95% CI -9.50 to 0.10) (low-quality evidence). Beta blocker (metoprolol, one trial, n = 140), when compared with placebo , significantly reduced systolic blood pressure by 4.20 mmHg (95% CI -8.12 to -0.28) but not diastolic blood pressure (-3.20 mmHg 95% CI -7.12 to 0.72) (low-quality evidence). Beta blocker/diuretic co …

Combination of tocolytic agents for inhibiting preterm labour.

BACKGROUND: Preterm birth represents the single largest cause of mortality and morbidity for newborns and a major cause of morbidity for pre … ersus IV magnesium sulphate plus IV fenoterol (one trial, 125 women); and, IV terbutaline plus oral metoprolol versus IV terbutaline alone (one trial, 17 women). Few studies with small numbers of women were available for each comparison, hence very little data were pooled in meta-analysis. In all trials, not many of the primary outcomes were reported.Three t …

Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies.

Beta-adrenergic receptor signaling regulates cellular processes associated with facilitating tumor cell proliferation and dampening anti-tumor immune response. These cellular processes may lead to compromised tumor control and cancer progression. Based on this ramification, Beta-blockers (BBs) have emerged as a potential treatment by inhibiting beta-adrenergic receptor signaling. This review aimed to investigate the relationship between the use of BBs and tumor progression and treatment response. Therefore, the authors explored several aspects: the potential synergistic relationship of BBs wit

Совпадение в полном тексте источника
… On the other hand, β1-SBBs have a β1 selectivity causing an antagonizing effect on the β1-receptor; examples of β1-SBB include isoprolol, metoprolol, and acebutolol ( Ripley and Saseen, 2014 ; Farzam and Jan, 2022 ). … Metoprolol Acebutolol Atenolol Betaxolol Celiprolol Esmolol Selective Beta2 blocker (SBB) | ICI | Selective inhibition of β2-receptor | Comparable effects to NSBB if β2 inhibition (ICI) occurs ( Cuesta et al., 2019 ; Del Vecchio et al., 2023 ; Satilmis et al., 2023 ) | Comparable to NSBB if β2 inhibition …

Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.

The increasing efficacy of cancer therapies has significantly improved survival rates, but it has also highlighted the prevalence of cancer-therapy-related cardiac dysfunction (CTRCD). This review provides a comprehensive overview of the identification, monitoring, and management of CTRCD, a condition resulting from several treatments, such as anthracyclines, HER2-targeted therapies, target therapies, and radiotherapy. The paper includes a discussion of the mechanisms of CTRCD associated with various cancer treatments. Early detection through serum biomarkers and advanced imaging techniques is

Совпадение в полном тексте источника
… succinate, or matching placebo | 10–61 weeks | 126 | Change in LVEF > 5% by CMR Metoprolol had no effect Candesartan protected against early LVEF decline vs. … Metoprolol and placebo group | Boekhout et al. [ 131 ] 2016 | Trastuzumab | Breast Cancer | Candesartan vs. placebo | 26 weeks | 206 | Decline in LVEF > 15% or a decrease in the LVEF <45% Candesartan had no effect | Akpek et al. [ 103 ] 2015 | Anthracyclines | Breast Cancer | Spironolactone vs. placebo …

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.

Anthracyclines remain a cornerstone of cancer therapy but are associated with a significant risk of cardiotoxicity, which can lead to overt heart failure. The risk is modulated by cumulative dose, pre-existing cardiovascular disease, and patient-specific factors. As cancer survival improves, the long-term cardiovascular consequences of anthracycline exposure have become a growing concern, underscoring the need for effective preventive strategies. This narrative review examines lifestyle and pharmacological interventions aimed at mitigating anthracycline-induced cardiotoxicity. Evidence suggest

Совпадение в полном тексте источника
… For instance, the PRADA trial (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy), which employed a 2 × 2 factorial design to assess candesartan cilexetil, metoprolol succinate, their combination, or placebo in early breast cancer patients receiving adjuvant epirubicin therapy, … Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Eur. Heart J. 2016 37 1671 1680 10.1093/eurheartj/ehw022 26903532 PMC4887703 93. Davis M.K. Villa D. …

Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.

At our institution, 2 of the initial 7 pregnant patients with confirmed coronavirus disease 2019 severe infection (28.6%; 95% CI, 8.2%-64.1%) developed cardiac dysfunction with moderately reduced left ventricular ejection fractions of 40%-45% and hypokinesis. Viral myocarditis and cardiomyopathy have also been reported in nonpregnant coronavirus disease 2019 patients. A case series of nonpregnant patients with coronavirus disease 2019 found that 33% of those in intensive care developed cardiomyopathy. More data are needed to ascertain the incidence of cardiomyopathy from coronavirus disease 20

Predictive Modeling of Pharmacokinetic Drug-Drug and Herb-Drug Interactions in Oncology: Insights From PBPK Studies.

Physiologically based pharmacokinetic (PBPK) modeling is increasingly used to anticipate, quantify, and strategically manage drug-drug (DDI) and herb-drug (HDI) interactions that can alter the exposure of chemotherapy agents together with co-administered phytochemicals or nutraceuticals. To evaluate current knowledge, we performed a comprehensive Google Scholar search (2003-2024) and selected studies that employed PBPK platforms, reported quantitative validation, and focused on chemotherapy-related interactions. From these reports, key modeling parameters, validation metrics, and clinically re

Совпадение в полном тексте источника
… C max AUC last C max AUC last C max AUC last IMATINIB Perpetrator Simvastatin acid (CML patients) CYP3A4 inhibition Strong inhibitor 3.84 4.91 2.05 2.99 1.87 1.65 Loer et al, 2024 28 Metoprolol (CML patients) CYP2D6 competitive inhibition CYP2D6 NMs Weak inhibitor 1.12 1.19 1.11 1.26 1.01 0.94 CYP2D6 … C max | AUC last | C max | AUC last | C max | AUC last IMATINIB | Perpetrator | Simvastatin acid (CML patients) | CYP3A4 inhibition | | Strong inhibitor | 3.84 | 4.91 | 2.05 | 2.99 | 1.87 | 1.65 | Loer et al, 2024 28 Metoprolol (CML patients) | CYP2D6 competitive inhibition | CYP2D6 NMs | Weak inhibitor …

Atypical Calcitriol-Mediated Hypercalcemia in Late Life: A Hypothesis-Generating Case.

Calcitriol-mediated hypercalcemia is most commonly associated with granulomatous disease or lymphoma and rarely occurs without an identifiable cause. We present the case of a 96-year-old woman who developed severe symptomatic hypercalcemia with elevated 1,25-dihydroxyvitamin D (calcitriol), low 25-hydroxyvitamin D (calcidiol), suppressed parathyroid hormone, and no evidence of malignancy, granulomatous disease, endocrine dysfunction, or vitamin D intoxication. She improved with intravenous fluids, calcitonin, and corticosteroids. We hypothesize that age-related impairment of the fibroblast gro

Совпадение в полном тексте источника
… Home medications included celecoxib, topical diclofenac, escitalopram, famotidine, furosemide, metoprolol, pregabalin, rosuvastatin, and pancrelipase. On arrival, she was difficult to arouse and disoriented. …

Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.

BackgroundThis article about the emerging field of cardio-oncology highlights typical side effects of oncological therapies in the cardiovascular system, cardiovascular complications of malignancies itself, and potential preventive or therapeutic modalities.MethodsWe performed a selective literature search in PubMed until September 2016.ResultsCardiovascular events in cancer patients can be frequently attributed to oncological therapies or to the underlying malignancy itself. Furthermore, many patients with cancer have pre-existing cardiovascular diseases that can be aggravated by the malignan

Совпадение в полном тексте источника
… Georgakopoulos P Roussou P Matsakas E Karavidas A Anagnostopoulos N Marinakis T Galanopoulos A Georgiakodis F Zimeras S Kyriakidis M Ahimastos A Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with … Fagerland MW Gravdehaug B von Knobelsdorff-Brenkenhoff F Bratland A Storas TH Hagve TA Rosjo H Steine K Geisler J Omland T Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol …

Pityriasis liechenoides et varioliformis acuta у пациента, лечащегося cevostamab.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… His daily medications included acyclovir, apixaban, atorvastatin, finasteride, metoprolol, omeprazole, and tamsulosin, all of which were started at least 4 months prior to presentation. …

Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.

BACKGROUND: Randomized controlled trials (RCTs) have yielded conflicting results regarding the ability of beta-blockers to influence periope … of the participants were previously taking beta-blockers. Types of beta-blockers were: propranolol, metoprolol, sotalol, esmolol, landiolol, acebutolol, timolol, carvedilol, nadolol, and atenolol. In twelve studies, beta-blockers were titrated according to heart rate or blood pressure. Duration of administration varied between studies, as did the time at whi …

Парастеральный перикардиоцентис для метициллина-сопротивляющегося Стафилокока ауреуса Перикардита, скомпрометированного Абсцессом и Тампонадой.

Перикардит (MRSA) является редким заболеванием и характеризуется высокой заболеваемостью и смертностью. Резюме дела: A 70-year-old Женщина с прошлым медицинским прошлым множеством миэломы, фибрилляциями, циррозом и сердечной анемией с уменьшенной фракцией выброса, покрытой болью в груди и диспной. Бактеремия MRSA из зараженного центрального венозного порта привела к септическому шоку и переднему перикардному абсцессу, что вызвало сердечный тампонад. Срочный парастеральный перикардиоцентез был выполнен, при этом флюифицированные культуры были положительными для МРСА. Несмотря на разрешение тамп

Совпадение в полном тексте источника
… On hospital day 15, an episode of ventricular tachycardia, hypoxia, fever with rigors, and elevated lactate level (8.5 mmol/L; reference: 0.5-1.6 mmol/L) prompted treatment for presumed septic versus cardiogenic shock entailing intravenous metoprolol tartrate, intravenous fluid resuscitation, empiric …

Sternal Tumor Resection and Complex Chest Wall Reconstruction of a Solitary Plasmacytoma: A Report of a Rare Case.

Localized sternal plasmacytoma is a rare and aggressive oncologic condition. Surgical resection followed by radiotherapy offers the highest chance of cure. Radical resection of the chest wall is technically feasible and is associated with improved outcomes. Subsequent reconstruction using meshes, plates, and both autologous and allogenic tissues allows for the restoration of chest wall function and may prolong survival. Patients with solitary plasmacytoma require close follow-up to monitor for local recurrence or distant disease progression. We present a case of a 63-year-old man diagnosed wit

Совпадение в полном тексте источника
… Additionally, the patient developed paroxysmal supraventricular tachycardia with a heart rate up to 180 bpm, which was pharmacologically controlled with intravenous metoprolol. Following stabilization of these complications, gradual weaning from mechanical ventilation was initiated. …

Aggressive systemic mastocytosis with multiple organ involvement: a case report.

Systemic mastocytosis is a rare malignancy whose main diagnostic finding is the abnormal proliferation of clonal mast cells. In this report, a 63-year-old woman is presented who was referred to the emergency department with lower back pain. Due to the hypereosinophilia in blood tests, a bone marrow biopsy was performed, and except for the presence of a large number of mastocytes, no other pathologic findings were seen. Furthermore, the immunohistochemistry test showed positive CD117 and CD25 markers, and the patient's platelet-derived growth factor receptor alpha test was positive. Hence, the

Совпадение в полном тексте источника
… She took a metoprolol tablet of 25 mg daily, a metformin tablet of 500 mg twice daily and a pantoprazole tablet of 40 mg twice daily. In the familial history, her mother died of gastric cancer. …